{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-038729","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.962142+00:00","generated_at":"2026-06-17T08:55:27.218365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BrainStorm FY2022 net loss $24.3M; cash drops to $3M; FDA ADCOM for NurOwn BLA","bullets":["Net loss of $24.3M ($0.66 per share) vs $24.5M ($0.68) in 2021; no revenue.","Cash and short-term deposits fell to $3M from $22M at year-end 2021.","R&D expenses $14M, G&A $10.9M; combined $24.9M operating spend.","FDA will hold Advisory Committee meeting to review NurOwn BLA for ALS; File over Protest used.","Dr. Stacy Lindborg promoted to Co-CEO in January 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-038729","json":"https://secwatch.observer/filing/0001104659-23-038729.json","markdown":"https://secwatch.observer/filing/0001104659-23-038729.md","text":"https://secwatch.observer/filing/0001104659-23-038729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923038729/0001104659-23-038729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923038729/tm2310964d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:55:27.218365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00c4036a6157834df6c39aeaed7af385e8d4115c","claim":"BRAINSTORM CELL THERAPEUTICS INC. reported the fiscal year ended December 31, 2022 results: net income approximately $30.3 million.","evidence_excerpt":"Net loss for the twelve months ended December 31, 2022, was approximately $","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923038729/0001104659-23-038729-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Net income","value":"approximately $30.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}